Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.
The study, published in the journal Clinical Cancer Research, was a collaborative effort between Paul B. Fisher, M.Ph., Ph.D., who originally discovered the mda-9/syntenin gene, and Santanu Dasgupta, Ph.D., an expert in bladder cancer research. Through cell cultures and mouse models of human bladder cancer, the researchers demonstrated that mda-9/syntenin helps to regulate bladder cancer growth and metastasis. They also showed that an increase in the gene's expression correlates with disease progression, making it a promising target for detecting and monitoring the growth and metastasis of bladder cancer. In addition, suppressing mda-9/syntenin expression resulted in a substantial decrease in cancer growth and its ability to spread.
"Currently, there are no biomarkers that can accurately predict bladder cancer metastasis, or monitor its progression," says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics program at VCU Massey, chairman of the Department of Human and Molecular Genetics at VCU School of Medicine and director of the VCU Institute of Molecular Medicine (VIMM). "Our findings could assist in the development of innovative ways to detect, monitor and treat bladder cancer."
The team discovered that mda-9/syntenin regulates bladder cancer progression by impacting epidermal growth factor receptor (EGFR) signaling. EGFR is located on the surface of bladder cancer cells and plays a part in a variety of mechanisms that contribute to cell proliferation, the growth of new blood vessels, cell migration and resistance to apoptosis - a form of cell suicide. The researchers showed that mda-9/syntenin physically binds to EGFR and disrupts a variety of processes that help keep cancer in check.
Fisher has previously shown that mda-9/syntenin is overexpressed in a variety of cancers and is a key contributor to metastasis in melanoma. Fisher and Dasgupta plan to continue exploring the role of mda-9/syntenin in the development of bladder cancer. Future studies will utilize animal models to determine the mechanisms by which the gene helps to initiate the disease in order determine the point at which the gene's expression indicates a positive cancer diagnosis.
"Bladder cancer is often diagnosed through an invasive procedure that involves inserting a flexible camera through the urethra, which may cause some people to delay testing and, in turn, treatment," says Dasgupta, member of the Cancer Molecular Genetics program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member. "We hope that our studies will lead to new, less invasive ways to detect and treat bladder cancer and, ultimately, fewer deaths."
Fisher and Dasgupta collaborated on this study with Devanand Sarkar, M.B.B.S., Ph.D., Harrison Research Scholar and member of the Cancer Molecular Genetics program at VCU Massey, associate professor in the Department of Human and Molecular Genetics at VCU School of Medicine and associate scientific director of cancer therapeutics at VIMM; Shilpa Bhatia, Ph.D., postdoctoral research scientist in the VCU Department of Human and Molecular Genetics; Swadesh K. Das, Ph.D., instructor in the VCU Department of Human and Molecular Genetics and VIMM member; Luni Emdad, M.B.B.S., Ph.D., member of the Cancer Molecular Genetics program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member; Aleksandar Janjic, research technician in the VCU Department of Human and Molecular Genetics; Mitchell E. Menezes, Ph.D., postdoctoral research scientist in the VCU Department of Human and Molecular Genetics; Nitai D. Mukhopadhyay, Ph.D., assistant professor in the Department of Biostatistics at VCU School of Medicine; and Chunbo Shao, M.D., Ph.D., postdoctoral research scientist in the Department of Otolaryngology at Johns Hopkins University in Baltimore, MD.
This study was supported by National Institutes of Health grant CA097318, the National Foundation for Cancer Research, the Elisa U Pardee Foundation and, in part, by VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.
The full manuscript of this study is available online at: http://clincancerres.
News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.
About VCU Massey Cancer Center
VCU Massey Cancer Center is one of only 67 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at http://www.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see http://www.